KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Astrazeneca (AZN) Current Leases (2017 - 2025)

Astrazeneca (AZN) has 3 years of Current Leases data on record, last reported at $382.0 million in Q4 2025.

  • For Q4 2025, Current Leases rose 12.68% year-over-year to $382.0 million; the TTM value through Dec 2025 reached $382.0 million, up 12.68%, while the annual FY2025 figure was $382.0 million, 12.68% up from the prior year.
  • Current Leases reached $382.0 million in Q4 2025 per AZN's latest filing, up from $339.0 million in the prior quarter.
  • Across five years, Current Leases topped out at $382.0 million in Q4 2025 and bottomed at $271.0 million in Q4 2023.
  • Average Current Leases over 3 years is $330.7 million, with a median of $339.0 million recorded in 2024.
  • Peak YoY movement for Current Leases: rose 25.09% in 2024, then increased 12.68% in 2025.
  • A 3-year view of Current Leases shows it stood at $271.0 million in 2023, then grew by 25.09% to $339.0 million in 2024, then rose by 12.68% to $382.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Current Leases were $382.0 million in Q4 2025, $339.0 million in Q4 2024, and $271.0 million in Q4 2023.